Vaccination against pandemic H1N1 (2009) in patients after allogeneic hematopoietic stem cell transplantation: a retrospective analysis
Seroconversion rates following influenza vaccination in patients with hematologic malignancies after...
SummaryBackground and objectives In 2009, the pandemic influenza A/H1N1 accounted for worldwide reco...
Background A novel, swine-origin influenza A (H1N1) virus was detected worldwide in April 2009, and ...
Purpose: Limited data are available on immunologic responses to primary pandemic H1N1 (2009) vacc...
Little data are available regarding the safety and immunologic response to pandemic H1N1 influenza v...
International audienceINTRODUCTION: Allogeneic hematopoietic stem cell transplantation (HSCT) is a m...
Background: During March 2009 a novel Influenza A virus emerged in Mexico. We describe the clinical ...
million people worldwide. Immunization with 1918-like and classical swine H1N1 virus vaccines result...
Objectives. To assess the 2009 influenza vaccine A/H1N1 on antibody response, side effects and disea...
OBJECTIVES: The efficacy of a novel vaccine against influenza virus A (H1N1) in patients with hemato...
We read with interest the paper by La Torre et al.,1 which conducted two systematic reviews and a me...
The world witnessed a the first influenza pandemic in this century and fourth overall since first fl...
Responses to influenza vaccines are poorly characterized in immunocompromised patients. The goal of ...
Clinical course of H1N1 infection in Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT) pati...
Seroconversion rates following influenza vaccination in patients with hematologic malignancies after...
Seroconversion rates following influenza vaccination in patients with hematologic malignancies after...
SummaryBackground and objectives In 2009, the pandemic influenza A/H1N1 accounted for worldwide reco...
Background A novel, swine-origin influenza A (H1N1) virus was detected worldwide in April 2009, and ...
Purpose: Limited data are available on immunologic responses to primary pandemic H1N1 (2009) vacc...
Little data are available regarding the safety and immunologic response to pandemic H1N1 influenza v...
International audienceINTRODUCTION: Allogeneic hematopoietic stem cell transplantation (HSCT) is a m...
Background: During March 2009 a novel Influenza A virus emerged in Mexico. We describe the clinical ...
million people worldwide. Immunization with 1918-like and classical swine H1N1 virus vaccines result...
Objectives. To assess the 2009 influenza vaccine A/H1N1 on antibody response, side effects and disea...
OBJECTIVES: The efficacy of a novel vaccine against influenza virus A (H1N1) in patients with hemato...
We read with interest the paper by La Torre et al.,1 which conducted two systematic reviews and a me...
The world witnessed a the first influenza pandemic in this century and fourth overall since first fl...
Responses to influenza vaccines are poorly characterized in immunocompromised patients. The goal of ...
Clinical course of H1N1 infection in Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT) pati...
Seroconversion rates following influenza vaccination in patients with hematologic malignancies after...
Seroconversion rates following influenza vaccination in patients with hematologic malignancies after...
SummaryBackground and objectives In 2009, the pandemic influenza A/H1N1 accounted for worldwide reco...
Background A novel, swine-origin influenza A (H1N1) virus was detected worldwide in April 2009, and ...
Add to ORKG